首页 | 本学科首页   官方微博 | 高级检索  
     

糖皮质激素联合非生物型人工肝治疗重症药物性肝损伤疗效及安全性
引用本文:贺娜,郑洋洋,齐云飞,朱绍华,张静,李娜,尹芳,周新民. 糖皮质激素联合非生物型人工肝治疗重症药物性肝损伤疗效及安全性[J]. 肝脏, 2017, 22(6)
作者姓名:贺娜  郑洋洋  齐云飞  朱绍华  张静  李娜  尹芳  周新民
作者单位:1. 719000,陕西省榆林市星元医院;2. 第四军医大学西京消化病医院;3. 解放军第十六医院
摘    要:目的评估糖皮质激素联合非生物型人工肝治疗重症药物性肝损伤的效果及安全性。方法对激素联合人工肝治疗的96例重症药物性肝损伤患者进行回顾性分析,记录其治疗过程及血常规、肝功能等指标,观察其有效率及并发症。结果 96例重症药物性肝损伤患者治疗有效者84例,无效12例,治疗后RBC(4.22±0.70)×109/L、Hb(127.88±22.99)g/L较前升高,差异有统计学意义(P0.05);ALT(145.48±158.94)U/L、AST(98.06±69.26)U/L、TBil(165.10±124.21)μmol/L、DBil(130.66±89.46)μmol/L、IBil(35.43±37.48)μmol/L、Alb(41.12±30.93)g/L、ALP(178.64±119.65)U/L较治疗前有明显改善,差异均有统计学意义(P0.05);BUN(5.61±2.59)mmol/L、Cre(61.00±14.36)μmol/L较前升高,差异有统计学意义(P0.05),血凝各指标较前无明显变化,差异无统计学意义(P0.05)。结论激素联合人工肝治疗重症药物性肝损伤患者,疗效肯定,安全性较好,可延缓病情进展,降低肝衰竭发生率。

关 键 词:药物性肝损伤  重症  激素  人工肝  疗效  安全性

Efficacy and safety of glucocorticoid with non-bioartificial liver support system in the treatment of severe drug-induced liver injury
HE Na,ZHENG Yang-yang,QI Yun-fei,ZHU Shao-hua,ZHANG Jing,LI Na,YIN Fang,ZHOU Xin-min. Efficacy and safety of glucocorticoid with non-bioartificial liver support system in the treatment of severe drug-induced liver injury[J]. Chinese Hepatology, 2017, 22(6)
Authors:HE Na  ZHENG Yang-yang  QI Yun-fei  ZHU Shao-hua  ZHANG Jing  LI Na  YIN Fang  ZHOU Xin-min
Abstract:Objective To evaluate efficacy and safety of glucocorticoid (GC) with non-bioartificial liver support system (NBLS) in the treatment of severe drug-induced liver injury (DILI).Methods In the retrospective study,96 cases with severe DILI who had underwent the treatment of GC combined NBLS in our hospital from January 2008 to December 2015 were enrolled.Treatment,blood routine,liver functions,and so on,were recorded.The efficacy and complications of GC combined with NBLS in treating severe DIM were observed.Results Treatment of GC combined with NBLS was effective in 84 cases (87.5%).Levels of red blood cell (RBC) (4.22 ± 0.70) × 109/L and hemoglobin (Hb) (127.88 ±22.99) g/L were significantly higher at baseline than those after treatment (P<0.05).Levels of alanine aminotransferase (ALT) (145.48± 158.94) U/L,aspartate amino transferase (AST)(98.06 ± 69.26) U/L,total bilirubin (TBil) (165.10 ± 124.21) μtmol/L bilirubin tra,direct bilirubin (DBil) (130.66 ± 89.46) μmol/L,indirect bilirubin (IBil) (35.43 ± 37.48) μmol/L,albumin (Alb) (41.12 ± 30.93) g/L and alkaline phosphatase (ALP) (178.64 ± 119.65) U/L were significantly improved compared to those before treatment (P<0.05).However,levels of blood urea nitrogen (BUN) (5.61 ± 2.59)mmol/L and cre-recombinase (Cre) (61.00 ± 14.36) μmol/L in renal function were significantly higher after treatment (P<0.05).No significant difference was observed in the level of prothrombin time (PT) and plasma thromboplastin antecedent (PTA) (P>0.05).Conclusion The treatment of GC with NBLS showed satisfactory effectiveness and safety for severe DILI,which could ameliorate the disease progression,reduce total incidence of liver failure and improve the prognosis.
Keywords:Drug-induced liver injury  Severe  Glucocorticoid non-bioartificial liver support system  Efficacy  Safety
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号